查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1300980

藥物警戒市場規模、份額和趨勢分析報告：按服務提供商、產品生命週期、治療領域、工藝流程、最終用途、產品類型和細分市場預測，2023-2030 年

Pharmacovigilance Market Size, Share & Trends Analysis Report By Service Provider (In-house, Contract Outsourcing), By Product Life Cycle, By Therapeutic Area, By Process Flow, By End-Use, By Type, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 298 Pages | 商品交期: 2-10個工作天內

價格

藥物警戒市場增長和趨勢

預計到 2030 年，全球藥物警戒市場將達到 118 億美元。

預計在預測期內復合年增長率為 7.0%。 市場增長的主要驅動力是副作用（ADR）發生率的增加。 ADR 給醫療保健系統帶來沉重負擔，是發達國家最明顯的發病來源之一。 根據美國國家生物技術信息中心 (NCBI) 的數據，在歐洲，每年因 ADR 住院的患者中約有二十分之一。 藥物警戒 (PV) 服務通過協助製造商在臨床試驗階段識別與藥物相關的不良反應發揮著重要作用。

此外，根據2022年2月發表在《當代醫學研究與實踐雜誌》上的文章《接受癌症化療藥物的患者藥物不良反應的嚴重性和結果——一項前瞻性觀察研究》文章顯示，嚴重的ADR每年導緻美國超過10萬人死亡，成為過去十年來最嚴重的健康問題。 致命性心律失常和肝功能衰竭等不良反應可能會導致藥物從市場上撤出，因為與藥物使用相關的風險超過了相關的益處。 COVID-19大流行對光伏服務提供商來說既是機遇也是挑戰，需要開發創新平台以提高其競爭力。

例如，2020 年 12 月，生命科學行業商業服務提供商 EVERSANA 與專門從事藥物開發流程自動化的生命科學軟件公司 ArisGlobal 合作。 該合作夥伴關係旨在將端到端 PV 程序數字化，以在全球範圍內實現更安全、更有效的醫療保健。 技術先進且用戶友好的軟件系統市場（例如基於雲的光伏和藥物安全平台）預計將在預測期內支持該行業的增長。 例如，Clinevo Technologies 提供 Clinevo Safety，這是一種基於雲的解決方案，涵蓋案例處理、監管提交/AS2 網關、PV 攝入、分析、安全信號等。

這個一體化平台正在引領市場。 此外，協調一致的努力正在支持巴西等新興市場的增長。 例如，巴西推出了涉及製藥行業、學術界、臨床實踐和衛生當局的患者安全和 PV 計劃。 該項目由 FIPFARMA（Fundacao Instituto de Pesquisas Farmaceuticas）和藥學院（聖保羅大學）提供，分兩批（2020 年和 2022 年）提供了 30 小時的在線課程。 該課程涵蓋了醫療保健和藥物警戒概述、藥物安全和管理以及患者安全文化等重要主題。 該研討會解決了醫療保健專業人員 (HCP) 面臨的現實挑戰，並鼓勵協作解決問題。

視頻會議有效地吸引了 HCP 並對其進行了教育，促進了知識共享，並促進了思維方式的轉變。 該倡議對參與者產生了積極影響，並加強了巴西的光伏實踐。 發達國家領先的製藥公司正在重點外包光伏服務，以降低成本並減少運營費用。 預計這將為發展中國家的合同研究組織（CRO）創造擴大其行業份額的機會。 製造商正在重新考慮他們的產品開發程序，以滿足全球患者不斷增長的需求。 由於這些因素，預計在預測期內對光伏服務的需求將會擴大。

此外，光伏行業的公司正在實施收購、合作、業務擴張和產品發布等戰略，以擴大其產品範圍並提高其在市場上的影響力。 例如，專門從事製藥行業的服務提供商 Ergomed plc 於 2022 年 2 月收購了 ADAMAS Consulting Group Limited。 ADAMAS 是一家提供藥品製造、臨床試驗審核和光伏系統質量保證服務的國際諮詢公司。 此次交易價值 2560 萬英鎊，預計將為 Ergomed 帶來盈利，並在未來提供進一步的增長和戰略優勢。

藥物警戒市場報告亮點

  • 第四階段佔據市場主導地位，到 2022 年銷售份額將超過 75%。 這是由於 ADR 事件和上市後監督的增加。
  • 隨著製藥公司尋求通過外包服務降低運營成本，2022 年合同外包將佔據服務提供商細分市場 60% 以上的市場份額。
  • 自願報告細分市場在 2022 年以超過 30% 的銷售份額引領市場。 其應用包括高效且經濟高效地檢測新型、嚴重和罕見的 ADR。
  • 在生物製藥公司在慢性癌症治療方面的研究努力的推動下，腫瘤學在 2022 年佔據治療領域的最大份額，超過 25%。
  • 預計在預測期內，流程領域的案例數據管理將以 7.3% 的最快複合年增長率增長。
  • 生物技術公司在最終用途領域的複合年增長率將達到 8.0%，是最快的。 這是因為我們專注於生物製劑、治療藥物和基因治療等新產品的研發。
  • 由於對新藥開發的投資、有利的監管以及在研究單位和臨床試驗方面的強大影響力，北美在 2022 年佔據了最大的收入份額，超過 30%。
  • 公司採用新產品發布、合作夥伴關係和收購等策略來獲得競爭優勢。

內容

第一章調查方法及範圍

  • 市場細分和範圍
  • 調查方法
  • 信息獲取
  • 信息或數據分析
  • 市場形成和驗證
  • 型號詳細信息
  • 輔助信息列表
  • 縮寫列表
  • 市場定義
  • 報告的目的

第 2 章執行摘要

第 3 章藥物警戒市場變量、趨勢和範圍

  • 市場體系展望
    • 母公司市場分析
    • 補充市場分析
  • 採用和增長前景圖
  • 藥物警戒市場動態
    • 市場驅動因素分析
    • 市場製約因素分析
    • 行業問題
  • 藥物警戒市場分析工具：Porter
  • SWOT 分析，按因素（政治/法律、經濟、技術）
  • 價值鏈分析
    • 臨床前
    • 臨床
    • PMA
  • 服務產品及其需求的生命週期映射
  • 監管框架
    • 按國家/地區劃分的監管機構列表
  • 組織結構簡介
  • 定價模型
    • 按活動分配藥品安全預算
    • 按開發階段劃分
    • 按治療領域
    • 價格水平
  • 技術時間表概述
    • 不斷變化的技術和採用
  • 新冠肺炎 (COVID-19) 的影響
    • 近期發展和戰略成就
    • 公司實施的戰略
  • 市場趨勢
    • 資源擴展
    • 藥物警戒自動化
  • 通貨膨脹的影響
  • 醫學寫作與醫療安全審查的比較分析
    • 2022 年醫學寫作市場展望
    • 2022 年醫療安全審查市場展望

第 4 章藥物警戒市場：產品生命週期估算和趨勢分析

  • 2022 年和 2030 年市場份額分析
  • 儀表板
  • 市場定義和範圍
    • 臨床前
    • 第一階段
    • 第二階段
    • 第三階段
    • 第四階段

第五章藥物警戒市場：服務提供商的估算和趨勢分析

  • 2022 年和 2030 年市場份額分析
  • 儀表板
  • 市場定義和範圍
    • 內部
    • 合同工作外包

第 6 章藥物警戒市場：類型估計和趨勢分析

  • 2022 年和 2030 年市場份額分析
  • 儀表板
  • 市場定義和範圍
    • 自願報告
    • 增強的 ADR 報告
    • 有針對性的自願報告
    • 群組事件監控 (CEM)
    • 電子病歷挖礦

第 7 章藥物警戒市場：工藝流程估計和趨勢分析

  • 2022 年和 2030 年市場份額分析
  • 儀表板
  • 市場定義和範圍
    • 案例數據管理
    • 信號檢測
    • 風險管理體系

第八章藥物警戒市場：治療領域預估及趨勢分析

  • 2022 年和 2030 年市場份額分析
  • 儀表板
  • 市場定義和範圍
    • 腫瘤
    • 神經
    • 心髒病學
    • 呼吸系統
    • 其他

第 9 章藥物警戒市場：最終用途估計和趨勢分析

  • 2022 年和 2030 年市場份額分析
  • 儀表板
  • 市場定義和範圍
    • 藥品
    • 生物科技公司
    • 醫療器械製造商
    • 其他

第 10 章藥物警戒市場：按地區、按產品、按服務提供商、按類型和最終用途進行估算和趨勢分析

  • 區域市場快照
  • 北美
    • 2018-2030 年北美藥物警戒市場估計和預測
    • 美國
    • 加拿大
  • 歐洲
    • 2018-2030 年歐洲藥物警戒市場估計和預測
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 俄羅斯
    • 丹麥
    • 挪威
    • 瑞典
  • 亞太地區
    • 2018-2030 年亞太地區藥物警戒市場估算和預測
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 泰國
    • 韓國
  • 拉丁美洲
    • 2018-2030 年拉丁美洲藥物警戒市場估計和預測
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 2018-2030 年中東和非洲藥物警戒市場估計和預測
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 科威特

第 11 章藥物警戒市場：競爭分析

  • 市場參與分類
  • 上市公司
    • 企業市場分析
    • 公司市場份額
  • 私人公司
    • 主要初創企業名單
  • 戰略合作和增加產品發布
  • 政府戰略舉措，包括合作
  • 競爭對手加強光伏意識計劃
  • 競爭對手加強合作和運營外包
  • 整合趨勢
  • 潛在客戶

第12章競爭格局

  • 公司簡介
    • ACCENTURE
    • CLINQUEST GROUP BV（LINICAL AMERICAS）
    • IQVIA
    • COGNIZANT
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • IBM CORPORATION
    • ARISGLOBAL
    • ICON PLC.
    • CAPGEMINI
    • ITCLINICAL
    • TAKE SOLUTIONS LIMITED
    • PAREXEL INTERNATIONAL CORPORATION.
    • BIOCLINICA, INC.
    • WIPRO
    • UNITED BIOSOURCE LLC
    • FMD K&L（CLINCHOICE）

第 13 章成功策略

第 14 章轉換成本分析

Product Code: 978-1-68038-327-0

Pharmacovigilance Market Growth & Trends

The global pharmacovigilance market size is projected to reach USD 11.8 billion by 2030, according to a new report by Grand View Research, Inc. It is anticipated to witness growth at a CAGR of 7.0% during the forecast period. The key factor responsible for the market growth is the growing incidence of Adverse Drug Reactions (ADR). ADR imposes a significant load on healthcare systems and is one of the evident grounds for morbidity in developed nations. As per the National Center for Biotechnology Information (NCBI), about 1 in 20 hospitalizations in Europe yearly are owing to ADR. Pharmacovigilance (PV) services play a vital role in the clinical trial phase by aiding manufacturers in recognizing the negative consequences associated with the drug.

Furthermore, a February 2022 article published in the Journal of Current Medicine Research and Practice titled "Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs - A Prospective Observational Study" revealed that serious ADRs in the U.S. result in over 100,000 deaths annually and have been a major health concern since the past decade. ADRs, such as fatal arrhythmia and liver failure, can result in drug withdrawal from the market as the risks related to the drug usage outweigh its associated benefits. The COVID-19 pandemic presented both opportunities and challenges for PV service providers, leading to the development of innovative platforms for a competitive edge.

For instance, in December 2020, EVERSANA, a commercial services provider in the life sciences industry, collaborated with ArisGlobal, a life sciences software company specializing in automating drug development processes. This partnership was aimed to digitally transform end-to-end PV procedures, ensuring safer and more effective healthcare worldwide. The market for technologically advanced and user-friendly software systems, like cloud-based PV and drug safety platforms, is anticipated to support industry growth over the forecast period. For instance, Clinevo Technologies offers Clinevo Safety, a cloud-based solution encompassing various functionalities, such as Case Processing, Regulatory Submissions/AS2 Gateway, PV Intake, Analytics, and Safety Signals.

This all-in-one platform is driving the market forward. Furthermore, organizational initiatives support the growth of emerging markets like Brazil. For instance, a collaborative Patient Safety and PV program was introduced in Brazil, involving the pharmaceutical industry, academia, clinical practice, and health authorities. Offered by FIPFARMA (Fundacao Instituto de Pesquisas Farmaceuticas) and Pharmacy College (Universidade de Sao Paulo), the program conducted a 30-hour online course in two cohorts (2020 and 2022). It covered crucial topics, such as Healthcare and Pharmacovigilance Overview, Drug Safety & Management, and Patient Safety Culture. Workshops addressed real Challenges Healthcare Professionals (HCPs) faced and encouraged collaborative problem-solving.

Video conferences effectively engaged and educated HCPs, facilitating knowledge sharing and promoting a mindset shift. This initiative positively impacted participants and enhanced PV practices in Brazil. Key pharma companies in developed nations are concentrating on outsourcing PV services to decrease costs and reduce operational expenses. This is expected to create an opportunity for Contact Research Organizations (CROs) in developing territories to acquire more industry share. Manufacturers are renovating their product development procedures to fulfill the growing patient needs worldwide. These factors are predicted to augment the demand for PV services over the forecast period.

Furthermore, PV industry players are implementing strategies like acquisitions, collaborations, expansions, and product launches to broaden their offerings and expand their market presence. For example, in February 2022, Ergomed plc, a specialized services provider to the pharmaceutical industry, acquired ADAMAS Consulting Group Limited. ADAMAS is an international consultancy that offers quality assurance services in pharmaceutical manufacturing, clinical trial auditing, and PV systems. The acquisition, valued at £25.6 million (in pounds), is expected to favor Ergomed's earnings, with further growth and strategic advantages anticipated in the future.

Pharmacovigilance Market Report Highlights

  • Phase IV dominated the market with a revenue share of over 75% in 2022. This was driven by increased ADR incidents and post-marketing surveillance
  • Contract outsourcing accounted for over 60% market share in the service provider segment in 2022, as pharmaceutical organizations aimed to reduce operational costs by outsourcing services
  • The spontaneous reporting type segment led the market with a revenue share of over 30% in 2022. Its applications include efficient and cost-effective detection of new, serious, and rare ADRs
  • Oncology held the largest share of over 25% in the therapeutic area segment in 2022, fueled by biopharmaceutical companies' research efforts in chronic cancer treatments
  • Case data management is anticipated to grow at the fastest CAGR of 7.3% in the process flow segment during the forecast period
  • Biotechnology companies are expected to have the fastest CAGR of 8.0% in the end-use segment. This is due to their focus on R&D for novel products, such as biologics, therapies, and gene therapies
  • North America held the largest revenue share of over 30% in 2022 due to investments in new drug development, favorable regulations, and a strong presence of research units and clinical trials
  • Companies are adopting strategies like new product launches, collaborations, and acquisitions to gain a competitive advantage

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Product Life Cycle
    • 1.1.2 Service Provider
    • 1.1.3 Type
    • 1.1.4 Process Flow
    • 1.1.5 Therapeutic Area
    • 1.1.6 End-Use
    • 1.1.7 Regional Scope
    • 1.1.8 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research:
    • 1.3.5 Details Of Primary Research
      • 1.3.5.1 Data For Primary Interviews In North America
      • 1.3.5.2 Data For Primary Interviews In Europe
      • 1.3.5.3 Data For Primary Interviews In Apac
      • 1.3.5.4 Data For Primary Interviews In Latin America
      • 1.3.5.5 Data For Primary Interviews In Mea
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Top Down Market Estimation
      • 1.6.1.2 Cagr Calculation
      • 1.6.1.3 Key Report Updates
  • 1.7 List Of Secondary Sources
  • 1.8 List Of Abbreviations
  • 1.9 Market Definitions
  • 1.10 Report Objectives
    • 1.10.1 Objective 1:
    • 1.10.2 Objective 2:

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot (Product Life Cycle & Service Provider)
  • 2.3 Segment Snapshot (Type & Therapeutic Area)
  • 2.4 Segment Snapshot (Process Flow & End Use)
  • 2.5 Competitive Landscape Snapshot

Chapter 3 Pharmacovigilance Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Analysis
    • 3.1.2 Ancillary Market Analysis
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Pharmacovigilance Market Dynamics
    • 3.3.1 Market Driver Analysis
      • 3.3.1.1 Growing Drug Consumption And Drug Development Rates
      • 3.3.1.2 Increasing Incidence Of Adr And Drug Toxicity
      • 3.3.1.3 Increasing Trend Of Outsourcing Pharmacovigilance Services
      • 3.3.1.4 Increasing Externalization Of Clinical Trial Studies By Large Pharmaceutical And Biopharmaceutical Companies
      • 3.3.1.5 Increasing Regulatory Burden On Manufacturers
      • 3.3.1.6 Introduction Of Technologically Advanced Software Services
      • 3.3.1.7 Constantly Rising Investment On R&D By Healthcare Companies
      • 3.3.1.8 Partnerships And Collaborations Between Market Players
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Shortage Of Skilled Labor
      • 3.3.2.2 Expensive Technology For Small And Mid-Sized Player
      • 3.3.2.3 Lack Of Recognition
      • 3.3.2.4 Scarcity Of Integration Standards
    • 3.3.3 Industry Challenges
  • 3.4 Pharmacovigilance Market Analysis Tools: Porters
  • 3.5 SWOT Analysis, By Factor (Political & Legal, Economic, And Technological)
  • 3.6 Value Chain Analysis
    • 3.6.1 Preclinical
    • 3.6.2 Clinical
    • 3.6.3 PMA
  • 3.7 Mapping of Life Cycle against Service Offering and Their Demand
  • 3.8 Regulatory Framework
    • 3.8.1 List Of Regulatory Bodies By Country
  • 3.9 Organization Structure Introduction
  • 3.10 Pricing Models
    • 3.10.1 Drug Safety Budget Allocation By Activities
    • 3.10.2 By Development Phase
    • 3.10.3 By Therapeutic Area
    • 3.10.4 Pricing Level
      • 3.10.4.1 Project Management
      • 3.10.4.2 Case Processing
      • 3.10.4.3 Adr Reporting
      • 3.10.4.4 Medical Writing
      • 3.10.4.5 Drug Safety Management
  • 3.11 Technology Timeline Overview
    • 3.11.1 Changing Technology & Adoption
      • 3.11.1.1 Social Media
      • 3.11.1.2 Literature Screening
      • 3.11.1.3 Automation And Ai
      • 3.11.1.4 Big Data Analytics In Pv
  • 3.12 Impact Of Covid-19
    • 3.12.1 Recent Developments & Strategic Outcomes
      • 3.12.1.1 Regulatory Requirements/Changes Due To Covid-19
    • 3.12.2 Strategies Implemented By Companies
      • 3.12.2.1 Iqvia
      • 3.12.2.2 Paraxel International Corporation
      • 3.12.2.3 Bioclinica
      • 3.12.2.4 Pharmaceutical Product Development (Ppd)
      • 3.12.2.5 Ibm Corporation
      • 3.12.2.6 Icon, Plc
      • 3.12.2.7 Pra Health Sciences
      • 3.12.2.8 Covance Inc
      • 3.12.2.9 Arisglobal
      • 3.12.2.10 Linical Accelovance
      • 3.12.2.11 Laboratory Corporation Of America Holdings
  • 3.13 Market Trends
    • 3.13.1 Scaling Of Resources
    • 3.13.2 Automation In Pharmacovigilance
  • 3.14 Impact Of Inflation
  • 3.15 Comparative Analysis Between Medical Writing Vs Medical Safety Review
    • 3.15.1 Medical Writing Market Outlook, 2022
      • 3.15.1.1 Medical Writing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 3.15.2 Medical Safety Review Market Outlook, 2022
      • 3.15.2.1 Medical Safety Review Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 4 Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis

  • 4.1 Product Life Cycle Market Share Analysis, 2022 & 2030
  • 4.2 Product Life Cycle Dashboard
  • 4.3 Market Definition And Scope
    • 4.3.1 Preclinical
      • 4.3.1.1 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.2 PHASE I
      • 4.3.2.1 Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.3 PHASE II
      • 4.3.3.1 Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.4 PHASE III
      • 4.3.4.1 Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.5 PHASE IV
      • 4.3.5.1 Phase IV market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5 Pharmacovigilance Market: Service Provider Estimates & Trend Analysis

  • 5.1 Service provider Market Share Analysis, 2022 & 2030
  • 5.2 Service Provider Dashboard
  • 5.3 Market definition and scope
    • 5.3.1 In House
      • 5.3.1.1 In House Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2 Contract Outsourcing
      • 5.3.2.1 Contract Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis

  • 6.1 Type Market Share Analysis, 2022 & 2030
  • 6.2 Type Dashboard
  • 6.3 Market definition and scope
    • 6.3.1 Spontaneous Reporting
      • 6.3.1.1 Spontaneous Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2 Intensified Adr Reporting
      • 6.3.2.1 Intensified Adr Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3 Targeted Spontaneous Reporting
      • 6.3.3.1 Targeted Spontaneous Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4 Cohort Event Monitoring (CEM)
      • 6.3.4.1 CEM market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.5 EHR Mining
      • 6.3.5.1 EHR Mining market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7 Pharmacovigilance Market: Process Flow Estimates & Trend Analysis

  • 7.1 Process Flow Market Share Analysis, 2022 & 2030
  • 7.2 Process Flow Dashboard
  • 7.3 Market definition and scope
    • 7.3.1 Case Data Management
      • 7.3.1.1 Case Data Management Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.1 Case Logging
      • 7.3.1.1.1.1 Case Logging Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.2 Case data analysis
      • 7.3.1.1.2.1 Case data analysis market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.3 Medical reviewing and reporting
      • 7.3.1.1.3.1 Medical reviewing and reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.2 Signal Detection
      • 7.3.2.1 Signal Detection Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.1.1 Adverse Event Logging
      • 7.3.2.1.1.1 Adverse Event Logging Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.1.2 Adverse Event Analysis
      • 7.3.2.1.2.1 Adverse Event Analysis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.1.3 Adverse Event Review & Reporting
      • 7.3.2.1.3.1 Adverse Event Review & Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3 Risk Mamangement System
      • 7.3.3.1 Risk Management System Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.3.3.1.1 Risk Evaluation System
      • 7.3.3.1.1.1 Risk Evaluation System Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.3.3.1.2 Risk Mitigation System
      • 7.3.2.1.2.1 Risk Mitigation System Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis

  • 8.1 Therapeutic Area Market Share Analysis, 2022 & 2030
  • 8.2 Therapeutic Area Dashboard
  • 8.3 Market definition and scope
    • 8.3.1 Oncology
      • 8.3.1.1 Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2 Neurology
      • 8.3.2.1 Neurology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3 Cardiology
      • 8.3.3.1 Cardiology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4 Respiratory Systems
      • 8.3.4.1 Respiratory Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5 Others
      • 8.3.5.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9 Pharmacovigilance Market: End-Use Estimates & Trend Analysis

  • 9.1 End-Use Market Share Analysis, 2022 & 2030
  • 9.2 End-Use Dashboard
  • 9.3 Market definition and scope
    • 9.3.1 Pharmacuticals
      • 9.3.1.1 Pharmaceuticals Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2 Biotechnology Companies
      • 9.3.2.1 Biotechnology Companies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.3 Medical Device Manufacturers
      • 9.3.3.1 Medical Device Manufacturers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.4 Others
      • 9.3.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 10 Pharmacovigilance Market: Regional Estimates & Trend Analysis, By, Product, Service Providers, Type, And End-Use

  • 10.1 Regional Market Snapshot
  • 10.2 North America
    • 10.2.1 North America Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 10.2.2 U.S.
      • 10.2.2.1 U.S. Pharmacovigilance Market Estimates And Forecasts, 2018- 2030(USD Million)
      • 10.2.2.2 Competitive Scenario
      • 10.2.2.3 Regulatory Framework
    • 10.2.3 Canada
      • 10.2.3.1 Canada Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.2.3.2 Competitive Scenario
      • 10.2.3.3 Regulatory Framework
  • 10.3 Europe
    • 10.3.1 Europe Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 10.3.2 UK
      • 10.3.2.1 UK Pharmacovigilance market estimates and Forecasts, 2018 - 2030(USD Million)
      • 10.3.2.2 Competitive scenario
      • 10.3.2.3 Regulatory Framework
    • 10.3.3 Germany
      • 10.3.3.1 Germany Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million
      • 10.3.3.2 Competitive Scenario
      • 10.3.3.3 Regulatory Framework
    • 10.3.4 France
      • 10.3.4.1 France Pharmacovigilance Market Estimates And Forecasts, 2018- 2030 (USD Million)
      • 10.3.4.2 Competitive Scenario
      • 10.3.4.3 Regulatory Framework
    • 10.3.5 Italy
      • 10.3.5.1 Italy Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.3.5.2 Competitive Scenario
      • 10.3.5.3 Regulatory Framework
    • 10.3.6 Spain
      • 10.3.6.1 Spain Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.3.6.2 Competitive Scenario
      • 10.3.6.3 Regulatory Framework
    • 10.3.7 Russia
      • 10.3.7.1 Russia Pharmacovigilance Market Estimates And Forecasts, 2018- 2030 (USD Million)
      • 10.3.7.2 Competitive Scenario
      • 10.3.7.3 Regulatory Framework
    • 10.3.8 Denmark
      • 10.3.8.1 Denmark Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030, (USD Million)
      • 10.3.8.2 Competitive Scenario
      • 10.3.8.3 Regulatory Framework
    • 10.3.9 Norway
      • 10.3.9.1 Norway Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030, (USD Million)
      • 10.3.9.2 Competitive Scenario
      • 10.3.9.3 Regulatory Framework
    • 10.3.10 Sweden
      • 10.3.10.1 Sweden Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030, (USD Million)
      • 10.3.10.2 Competitive Scenario
      • 10.3.10.3 Regulatory Framework
  • 10.4 Asia Pacific
    • 10.4.1 Asia Pacific Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 10.4.2 Japan
      • 10.4.2.1 Japan Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.4.2.2 Competitive Scenario
      • 10.4.2.3 Regulatory Framework
    • 10.4.3 China
      • 10.4.3.1 China Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.4.3.2 Competitive Scenario
      • 10.4.3.3 Regulatory Framework
    • 10.4.4 India
      • 10.4.4.1 India Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.4.4.2 Competitive Scenario
      • 10.4.4.3 Regulatory Framework
    • 10.4.5 Australia
      • 10.4.5.1 Australia Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.4.5.2 Competitive Scenario
      • 10.4.5.3 Regulatory Framework
    • 10.4.6 Thailand
      • 10.4.6.1 Thailand Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.4.6.2 Competitive Scenario
      • 10.4.6.3 Regulatory Framework
    • 10.4.7 South Korea
      • 10.4.7.1 South Korea Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.4.7.2 Competitive Scenario
      • 10.4.7.3 Regulatory Framework
  • 10.5 Latin America
    • 10.5.1 Latin America Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 10.5.2 Brazil
      • 10.5.2.1 Brazil Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.5.2.2 Competitive Scenario
      • 10.5.2.3 Regulatory Framework
    • 10.5.3 Mexico
      • 10.5.3.1 Mexico Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.5.3.2 Competitive Scenario
      • 10.5.3.3 Regulatory Framework
    • 10.5.4 Argentina
      • 10.5.4.1 Argentina Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.5.4.2 Competitive Scenario
      • 10.5.4.3 Regulatory Framework
  • 10.6 MEA
    • 10.6.1 MEA Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 10.6.2 South Africa
      • 10.6.2.1 South Africa Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.6.2.2 Competitive Scenario
      • 10.6.2.3 Regulatory Framework
    • 10.6.3 Saudi Arabia
      • 10.6.3.1 Saudi Arabia Pharmacovigilance Market Estimates And Forecasts, 2018- 2030(USD Million)
      • 10.6.3.2 Competitive Scenario
      • 10.6.3.3 Regulatory Framework
    • 10.6.4 UAE
      • 10.6.4.1 UAE Arabia Pharmacovigilance Market Estimates And Forecasts, 2018- 2030(USD Million)
      • 10.6.4.2 Competitive Scenario
      • 10.6.4.3 Regulatory Framework
    • 10.6.5 Kuwait
      • 10.6.5.1 Kuwait Pharmacovigilance Market Estimates And Forecasts, 2018- 2030(USD Million)
      • 10.6.5.2 Competitive Scenario
      • 10.6.5.3 Regulatory Framework

Chapter 11 Pharmacovigilance Market: Competitive Analysis

  • 11.1 Market Participation Categorization
  • 11.2 Public Companies
    • 11.2.1 Company Market Position Analysis
    • 11.2.2 Company Market Share
  • 11.3 Private Companies
    • 11.3.1 List Of Key Emerging Companies
  • 11.4 Increasing strategic collaborations and product launch
  • 11.5 Strategic Government initiatives which include collaborations
  • 11.6 Competitors increased PV awareness program
  • 11.7 Competitors increased collaboration and outsourcing of operations
  • 11.8 Consolidation Trends
  • 11.9 Potential Customers

Chapter 12 Competitive Landscape

  • 12.1 Company Profiles
    • 12.1.1 ACCENTURE
      • 12.1.1.1 Company overview
      • 12.1.1.2 Service benchmarking
      • 12.1.1.3 Financial performance
      • 12.1.1.4 Strategic initiatives
      • 12.1.1.5 SWOT Analysis
    • 12.1.2 CLINQUEST GROUP B.V. (LINICAL AMERICAS)
      • 12.1.2.1 Company overview
      • 12.1.2.2 Service benchmarking
      • 12.1.2.3 Financial performance
      • 12.1.2.4 Strategic initiatives
      • 12.1.2.5 SWOT Analysis
    • 12.1.3 IQVIA
      • 12.1.3.1 Company overview
      • 12.1.3.2 Service benchmarking
      • 12.1.3.3 Financial performance
      • 12.1.3.4 Strategic initiatives
      • 12.1.3.5 SWOT Analysis
    • 12.1.4 COGNIZANT
      • 12.1.4.1 Company overview
      • 12.1.4.2 Service benchmarking
      • 12.1.4.3 Financial performance
      • 12.1.4.4 Strategic initiatives
      • 12.1.4.5 SWOT Analysis
    • 12.1.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 12.1.5.1 Company overview
      • 12.1.5.2 Service benchmarking
      • 12.1.5.3 Financial performance
      • 12.1.5.4 Strategic initiatives
      • 12.1.5.5 SWOT Analysis
    • 12.1.6 IBM CORPORATION
      • 12.1.6.1 Company overview
      • 12.1.6.2 Service benchmarking
      • 12.1.6.3 Financial performance
      • 12.1.6.4 Strategic initiatives
      • 12.1.6.5 SWOT Analysis
    • 12.1.7 ARISGLOBAL
      • 12.1.7.1 Company overview
      • 12.1.7.2 Service benchmarking
      • 12.1.7.3 Financial performance
      • 12.1.7.4 Strategic initiatives
      • 12.1.7.5 SWOT Analysis
    • 12.1.8 ICON PLC.
      • 12.1.8.1 Company overview
      • 12.1.8.2 Service benchmarking
      • 12.1.8.3 Financial performance
      • 12.1.8.4 Strategic initiatives
      • 12.1.8.5 SWOT Analysis
    • 12.1.9 CAPGEMINI
      • 12.1.9.1 Company overview
      • 12.1.9.2 Service benchmarking
      • 12.1.9.3 Financial performance
      • 12.1.9.4 Strategic initiatives
      • 12.1.9.5 SWOT Analysis
    • 12.1.10 ITCLINICAL
      • 12.1.10.1 Company overview
      • 12.1.10.2 Service benchmarking
      • 12.1.10.3 Financial performance
      • 12.1.10.4 Strategic initiatives
      • 12.1.10.5 SWOT Analysis
    • 12.1.11 TAKE SOLUTIONS LIMITED
      • 12.1.11.1 Company overview
      • 12.1.11.2 Service benchmarking
      • 12.1.11.3 Financial performance
      • 12.1.11.4 Strategic initiatives
      • 12.1.11.5 SWOT Analysis
    • 12.1.12 PAREXEL INTERNATIONAL CORPORATION.
      • 12.1.12.1 Company overview
      • 12.1.12.2 Service benchmarking
      • 12.1.12.3 Financial performance
      • 12.1.12.4 Strategic initiatives
      • 12.1.12.5 SWOT Analysis
    • 12.1.13 BIOCLINICA, INC.
      • 12.1.13.1 Company overview
      • 12.1.13.2 Service benchmarking
      • 12.1.13.3 Financial performance
      • 12.1.13.4 Strategic initiatives
      • 12.1.13.5 SWOT Analysis
    • 12.1.14 WIPRO
      • 12.1.14.1 Company overview
      • 12.1.14.2 Service benchmarking
      • 12.1.14.3 Financial performance
      • 12.1.14.4 Strategic initiatives
      • 12.1.14.5 SWOT Analysis
    • 12.1.15 UNITED BIOSOURCE LLC
      • 12.1.15.1 Company overview
      • 12.1.15.2 Service benchmarking
      • 12.1.15.3 Financial performance
      • 12.1.15.4 Strategic initiatives
      • 12.1.15.5 SWOT Analysis
    • 12.1.16 FMD K&L (CLINCHOICE)
      • 12.1.16.1 Company overview
      • 12.1.16.2 Service benchmarking
      • 12.1.16.3 Financial performance
      • 12.1.16.4 Strategic initiatives
      • 12.1.16.5 SWOT Analysis

Chapter 13 Winning Strategies

  • 13.1 Key Winning/Scoring Criteria
    • 13.1.1 BY Categories
      • 13.1.1.1 Pharmaceuticals
      • 13.1.1.2 Biotech companies
      • 13.1.1.3 Medical device companies
  • 13.2 Key Vendor Selection Factors
    • 13.2.1 BY Category
    • 13.2.2 By Company Size
      • 13.2.2.1 Key Takeways

Chapter 14 Switching Cost Analysis

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of Abbreviation
  • TABLE 3 Types of ADRs
  • TABLE 4 Adverse Drug Events (ADEs) in hospitals
  • TABLE 5 Pharmacovigilance outsourcing services insights
  • TABLE 6 List of regulations, by country
  • TABLE 7 Estimated Total Per-Study Costs (in $ Millions), by Phase and Therapeutic Area
  • TABLE 8 Case management costing by year
  • TABLE 9 Price by case processing volume
  • TABLE 10 Subscription services for medical manuscript writing
  • TABLE 11 Total literature searches (2013-2022)
  • TABLE 12 Instances of failed phase I clinical trials for COVID-19 vaccine
  • TABLE 13 Recruiting phase II clinical trials for oncology
  • TABLE 14 Outsourcing trend observed in pharmaceutical companies
  • TABLE 15 Recent Market Events
  • TABLE 16 List of Major Deals & Acquisitions
  • TABLE 17 North America pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 18 North America pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 19 North America pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 20 North America pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 21 North America pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 22 North America pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 23 U.S. pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 24 U.S. pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 25 U.S. pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 26 U.S. pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 27 U.S. pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 28 U.S. pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 29 Canada pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 30 Canada pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 31 Canada pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 32 Canada pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 33 Canada pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 34 Canada pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 35 Europe pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 36 Europe pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 37 Europe pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 38 Europe pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 39 Europe pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 40 Europe pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 41 UK pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 42 UK pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 43 UK pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 44 UK pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 45 UK pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 46 UK pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 47 Germany pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 48 Germany pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 49 Germany pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 50 Germany pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 51 Germany pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 52 Germany pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 53 France pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 54 France pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 55 France pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 56 France pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 57 France pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 58 France pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 59 Italy pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 60 Italy pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 61 Italy pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 62 Italy pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 63 Italy pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 64 Italy pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 65 Spain pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 66 Spain pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 67 Spain pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 68 Spain pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 69 Spain pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 70 Spain pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 71 Russia pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 72 Russia pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 73 Russia pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 74 Russia pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 75 Russia pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 76 Russia pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 77 Denmark pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 78 Denmark pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 79 Denmark pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 80 Denmark pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 81 Denmark pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 82 Denmark pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 83 Norway pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 84 Norway pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 85 Norway pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 86 Norway pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 87 Norway pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 88 Norway pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 89 Sweden pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 90 Sweden pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 91 Sweden pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 92 Sweden pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 93 Sweden pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 94 Sweden pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 95 Asia Pacific pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 96 Asia Pacific pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 97 Asia Pacific pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 98 Asia Pacific pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 99 Asia Pacific pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 100 Asia Pacific pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 101 Japan pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 102 Japan pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 103 Japan pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 104 Japan pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 105 Japan pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 106 Japan pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 107 China pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 108 China pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 109 China pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 110 China pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 111 China pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 112 China pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 113 India pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 114 India pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 115 India pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 116 India pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 117 India pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 118 India pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 119 Australia pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 120 Australia pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 121 Australia pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 122 Australia pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 123 Australia pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 124 Australia pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 125 Thailand pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 126 Thailand pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 127 Thailand pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 128 Thailand pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 129 Thailand pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 130 Thailand pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 131 South Korea pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 132 South Korea pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 133 South Korea pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 134 South Korea pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 135 South Korea pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 136 South Korea pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 137 Latin America pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 138 Latin America pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 139 Latin America pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 140 Latin America pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 141 Latin America pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 142 Latin America pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 143 Brazil pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 144 Brazil pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 145 Brazil pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 146 Brazil pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 147 Brazil pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 148 Brazil pharmacovigilance market, by end use, 2017- 2030 (USD Million
  • TABLE 149 Mexico pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 150 Mexico pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 151 Mexico pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 152 Mexico pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 153 Mexico pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 154 Mexico pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 155 Argentina pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 156 Argentina pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 157 Argentina pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 158 Argentina pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 159 Argentina pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 160 Argentina pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 161 MEA pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 162 MEA pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 163 MEA pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 164 MEA pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 165 MEA pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 166 MEA pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 167 South Africa pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 168 South Africa pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 169 South Africa pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 170 South Africa pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 171 South Africa pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 172 South Africa pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 173 Saudi Arabia pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 174 Saudi Arabia pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 175 Saudi Arabia pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 176 Saudi Arabia pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 177 Saudi Arabia pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 178 Saudi Arabia pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 179 UAE pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 180 UAE pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 181 UAE pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 182 UAE pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 183 UAE pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 184 UAE pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 185 Kuwait pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 186 Kuwait pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 187 Kuwait pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 188 Kuwait pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 189 Kuwait pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 190 Kuwait pharmacovigilance market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Pharmacovigilance market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Primary interviews in North America
  • Fig. 6 Primary interviews in Europe
  • Fig. 7 Primary interviews in APAC
  • Fig. 8 Primary interviews in Latin America
  • Fig. 9 Primary interviews in MEA
  • Fig. 10 Market research approaches
  • Fig. 11 Value-chain-based sizing & forecasting
  • Fig. 12 QFD modeling for market share assessment
  • Fig. 13 Market formulation & validation
  • Fig. 14 Timeline of pharmacovigilance for a drug from development (premarket to post marketing)
  • Fig. 15 Market Snapshot
  • Fig. 16 Segment Snapshot (Product Life Cycle & Service Provider)
  • Fig. 17 Segment Snapshot (Type & Therapeutic Area)
  • Fig. 18 Segment Snapshot (Process Flow & End Use))
  • Fig. 19 Competitive Landscape Snapshot
  • Fig. 20 Penetration & growth prospect mapping
  • Fig. 21 Pharmacovigilance market dynamics
  • Fig. 22 Porter's five force model
  • Fig. 23 Pharmacovigilance - SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 24 Pharmacovigilance & Patient Safety Services - Product Life Cycle
  • Fig. 25 PV department
  • Fig. 26 PV organization structure
  • Fig. 27 Estimated budget allocation of drug safety activities at global and country-level
  • Fig. 28 Comparison between estimated global and country-level drug safety budget allocation
  • Fig. 29 Average % of drug safety budget contributed by function at a global level
  • Fig. 30 Pharmacovigilance system cost for small-sized firms and larger-sized firms
  • Fig. 31 Clinical trial cost by phase (%)
  • Fig. 32 Selected clinical trials costs based on technology
  • Fig. 33 Estimated cost of developing therapeutic medical device in the U.S.
  • Fig. 34 The average monthly cost of illness due to ADRs
  • Fig. 35 Medical Writers Employers by Industry
  • Fig. 36 Trending topics on social media (2017)
  • Fig. 37 ADR detection and from social media data
  • Fig. 38 Common literature automation tool flow
  • Fig. 39 Automation processes in PV
  • Fig. 40 Deterrents to Leveraging the Cloud (Oracle Survey)
  • Fig. 41 The three-step process to compute signal statistics from search log using big data
  • Fig. 42 Risk Management Capacity &Capability with Pharmacovigilance Using Big Data
  • Fig. 43 Pharma & Biotech R&D expense growth, 2020 (%)
  • Fig. 44 Medical writing market outlook, 2022 (USD Million)
  • Fig. 45 Medical writing market, 2018 - 2030 (USD Million)
  • Fig. 46 Global medical safety review market, 2018 - 2030 (USD Million)
  • Fig. 47 Pharmacovigilance market: Product life cycle movement analysis
  • Fig. 48 Pharmacovigilance market product life cycle dashboard
  • Fig. 49 Global Preclinical market, 2018 - 2030 (USD Million)
  • Fig. 50 Global Phase I market, 2018 - 2030 (USD Million)
  • Fig. 51 Global Phase II market, 2018 - 2030 (USD Million)
  • Fig. 52 Global Phase III market, 2018 - 2030 (USD Million)
  • Fig. 53 Adverse events reported in FAERS system, 2019-2022
  • Fig. 54 Global Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 55 Pharmacovigilance market: Service provider movement analysis
  • Fig. 56 Pharmacovigilance Service provider dashboard
  • Fig. 57 Global In-house market, 2018 - 2030 (USD Million)
  • Fig. 58 Global contract outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 59 Pharmacovigilance market: Type movement analysis
  • Fig. 60 Pharmacovigilance type dashboard
  • Fig. 61 Global spontaneous reporting market, 2018 - 2030 (USD Million)
  • Fig. 62 Global intensified ADR reporting market, 2018 - 2030 (USD Million)
  • Fig. 63 Global targeted spontaneous reporting market, 2018 - 2030 (USD Million)
  • Fig. 64 Global CEM market, 2018 - 2030 (USD Million)
  • Fig. 65 Global EHR mining market, 2018 - 2030 (USD Million)
  • Fig. 66 Pharmacovigilance market: Process flow movement analysis
  • Fig. 67 Pharmacovigilance market process flow dashboard
  • Fig. 68 Global case data management market, 2018 - 2030 (USD Million)
  • Fig. 69 Global case logging market, 2018 - 2030 (USD Million)
  • Fig. 70 Global case data analysis market, 2018 - 2030 (USD Million)
  • Fig. 71 Global medical reviewing and reporting market, 2018 - 2030 (USD Million)
  • Fig. 72 Global signal detection market, 2018 - 2030(USD Million)
  • Fig. 73 Global adverse event logging market, 2018 - 2030 (USD Million)
  • Fig. 74 Global adverse event analysis market, 2018 - 2030 (USD Million)
  • Fig. 75 Global adverse event review & reporting market, 2018 - 2030 (USD Million)
  • Fig. 76 Global risk management system market, 2018 - 2030 (USD Million)
  • Fig. 77 Global Risk Evaluation System market, 2018 - 2030 (USD Million)
  • Fig. 78 Global risk mitigation system market, 2018 - 2030 (USD Million)
  • Fig. 79 Pharmacovigilance market: Therapeutic area movement analysis
  • Fig. 80 Pharmacovigilance market therapeutic area dashboard
  • Fig. 81 Global oncology market, 2018 - 2030 (USD Million)
  • Fig. 82 Global neurology market, 2018 - 2030 (USD Million)
  • Fig. 83 Global cardiology market, 2018 - 2030 (USD Million)
  • Fig. 84 Global respiratory systems market, 2018 - 2030 (USD Million)
  • Fig. 85 Global others market, 2018 - 2030 (USD Million)
  • Fig. 86 Pharmacovigilance market: End-use movement analysis
  • Fig. 87 Pharmacovigilance market end-use dashboard
  • Fig. 88 Global pharmaceuticals market, 2018 - 2030 (USD Million)
  • Fig. 89 Global biotechnology companies' market, 2018 - 2030 (USD Million)
  • Fig. 90 Global medical device manufacturers market, 2018 - 2030 (USD Million)
  • Fig. 91 Global others market, 2018 - 2030 (USD Million)
  • Fig. 92 Regional market place: Key takeaways
  • Fig. 93 North America pharmacovigilance market, 2018- 2030 (USD Million)
  • Fig. 94 U.S. key country dynamics
  • Fig. 95 U.S. key country dynamics
  • Fig. 96 U.S. pharmacovigilance market, 2018 - 2030(USD Million)
  • Fig. 97 Canada key country dynamics
  • Fig. 98 Canada key country dynamics
  • Fig. 99 Canada pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 100 Europe pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 101 UK key country dynamics
  • Fig. 102 UK key country dynamics
  • Fig. 103 UK pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 104 Germany key country dynamics
  • Fig. 105 Germany key country dynamics
  • Fig. 106 Germany pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 107 France key country dynamics
  • Fig. 108 France key country dynamics
  • Fig. 109 France pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 110 Italy key country dynamics
  • Fig. 111 Italy key country dynamics
  • Fig. 112 Italy pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 113 Spain key country dynamics
  • Fig. 114 Spain key country dynamics
  • Fig. 115 Spain pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 116 Russia key country dynamics
  • Fig. 117 Russia pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 118 Denmark key country dynamics
  • Fig. 119 Denmark key country dynamics
  • Fig. 120 Denmark pharmacovigilance market estimates and forecasts, 2018 - 2030, (USD Million)
  • Fig. 121 Norway key country dynamics
  • Fig. 122 Norway key country dynamics
  • Fig. 123 Norway pharmacovigilance market estimates and forecasts, 2018 - 2030, (USD Million)
  • Fig. 124 Sweden key country dynamics
  • Fig. 125 Sweden key country dynamics
  • Fig. 126 Sweden pharmacovigilance market estimates and forecasts, 2018 - 2030, (USD Million)
  • Fig. 127 Asia Pacific Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 130 Japan pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 131 China key country dynamics
  • Fig. 132 China key country dynamics
  • Fig. 133 China pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 134 India key country dynamics
  • Fig. 135 India key country dynamics
  • Fig. 136 India pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 139 Australia pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 140 Thailand key country dynamics
  • Fig. 141 Thailand key country dynamics
  • Fig. 142 Thailand pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 145 South Korea pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 146 Latin America pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 149 Brazil pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 150 Mexico key country dynamics
  • Fig. 152 Mexico pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 155 Argentina pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 156 MEA pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 159 South Africa pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 162 Saudi Arabia pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 163 UAE key country dynamics
  • Fig. 164 UAE key country dynamics
  • Fig. 165 UAE pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 167 Kuwait pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 168 Market participant categorization
  • Fig. 169 Company market position analysis
  • Fig. 170 Estimated company market share analysis, 2022 (%)
  • Fig. 171 SWOT - Accenture
  • Fig. 172 SWOT - Linical Americas
  • Fig. 173 SWOT - IQVIA
  • Fig. 174 SWOT - Cognizant
  • Fig. 175 SWOT - Laboratory Corporation of America Holdings
  • Fig. 176 SWOT - IBM Corporation
  • Fig. 177 SWOT - ArisGlobal
  • Fig. 178 SWOT - ICON plc
  • Fig. 179 SWOT - Capgemini
  • Fig. 180 SWOT - ITClinical
  • Fig. 181 SWOT - Take Solutions
  • Fig. 182 SWOT - Parexel International Corporation
  • Fig. 183 SWOT - Clario
  • Fig. 184 SWOT - Wipro
  • Fig. 185 SWOT - United BioSource LLC
  • Fig. 186 SWOT - FMD K&L
  • Fig. 187 Commonly outsourced PV activities
  • Fig. 188 Vendor selection criteria